Association between body iron stores and the risk of acute myocardial infarction in men

Circulation

Volumn 97, Issue 15, 1998, Pages 1461-1466

  Tuomainen, Tomi Pekka ^b   Punnonen, Kari ^b   Nyyssönen, Kristiina ^b   Salonen, Jukka T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NONE

Author keywords

Coronary disease; Diabetes mellitus; Ferritin; Myocardial infarction; Population

Indexed keywords

FERRITIN; IRON; TRANSFERRIN RECEPTOR;

ACUTE HEART INFARCTION; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON METABOLISM; IRON STORAGE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR DENSITY; RISK ASSESSMENT; RISK FACTOR;

EID: 0032554685     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.15.1461     Document Type: Article

References (48)

1. Gutteridge JM, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin Haematol. 1989;2:195-256.
2. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990;186:1-85.
3. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294.
4. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86: 803-811.
5. Salonen JT, Nyyssönen K, Salonen R. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;331:1159. Letter.
6. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
7. Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb. 1991;11:1700-1711.
8. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
9. Weiner MA, Paige SB, Bailey SR. Antioxidant therapy decreases atherosclerotic plaque burden in an iron loaded animal model. Eur Heart J. 1994;425(suppl 15):2241. Abstract.
10. Araujo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, Montano RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol. 1995; 15:1172-1180.
11. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
12. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett. 1995;368:513-515.
13. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology. 1994;5:243-246.
14. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994;89:102-108.
15. Tuomainen T-P, Salonen R, Nyyssönen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314:793-794.
16. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation. 1994;89:2915-2918.
17. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330:1119-1124.
18. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139:704-712.
19. Mänttäri M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, Frick MH. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J. 1994;15:1599-1603.
20. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89:969-974.
21. Reunanen A, Takkunen H, Knekt P, Seppänen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med. 1995;238:223-230.
22. Van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol. 1995;24: 665-670.
23. Salonen JT. The role of iron an a cardiovascular risk factor. Curr Opin Lipidol. 1993;4:277-282.
24. Salonen JT. Body iron stores, lipid peroxidation and coronary heart disease. In: Hallberg L, Asp N-G, eds. Iron Nutrition in Health and Disease. London, UK: JL London Press; 1996:293-301.
25. Sempos CT, Looker AC, Gillum RF. Iron and heart disease: the epidemiologic data. Nutr Rev. 1996;54:73-84.
26. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood. 1990;75:1870-1876.
27. Cook JD, Skikne B, Baynes R. The use of the serum ferritin receptor for the assessment of iron status. In: Hallberg L, Asp N-G, eds. Iron Nutrition in Health and Disease. London, UK: JL London Press; 1996:49-58.
28. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res. 1988;20:46-50.
29. Tuomilehto J, Arstila M, Kaarsalo E, Kankaanpää J, Ketonen M, Kuulasmaa K, Lehto S, Miettinen H, Mustaniemi H, Palomäki P, Puska P, Pyörälä K, Salomaa V, Torppa J, Vuorenmaa T. Acute myocardial infarction (AMI) in Finland: baseline data from the FINMONICA AMI register in 1983-1985. Eur Heart J. 1992;13:577-587.
30. 3, subfractions, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation. 1991;84:129-139.
31. Salonen JT, Seppänen K, Nyyssönen K, Korpela H, Kauhanen J, Kantola M, Tuomilehto J, Esterbauer H, Tatzber F, Salonen R. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation. 1995;91:645-655.
32. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended method for the determination of γ-glutamyl-transferase in blood. Scand J Clin Invest. 1976; 36:119-125.
33. Lakka TA, Venalainen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 1994;330:1549-1554.
34. Kauhanen J, Julkunen J, Salonen JT. Coping with inner feelings and stress: heavy alcohol use in the context of alexithymia. Behav Med. 1992;18:121-126.
35. Ihanainen M, Salonen R, Seppänen R, Salonen JT. Nutrition data collection in the Kuopio Ischaemic Heart Disease Risk Factor Study: nutrient intake of middle-aged eastern Finnish men. Nutr Res. 1989;9:89-95.
36. Fidenza F. Nutritional Status Assessment: A Manual for Population Studies. London, UK: Chapman & Hall; 1991.
37. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997; 89:1052-1057.
38. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents: studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med. 1990;9:299-305.
39. Subar AF, Block G. Use of vitamin and mineral supplements: demographics and amounts of nutrients consumed: the 1987 Health Interview Survey. Am J Epidemiol. 1990;132:1091-1101.
40. Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH. Aspirin use and cognitive function in the elderly. Am J Epidemiol. 1996;143: 683-691.
41. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13:1139-1158.
42. Nyyssönen K, Salonen R, Korpela H, Salonen JT. Elevation of serum high-density lipoprotein cholesterol concentration due to lowering of body iron stores by blood letting. Eur J Lab Med. 1994;2:113-115.
43. Salonen JT, Korpela H, Nyyssönen K, Porkkala E, Tuomainen T-P, Belcher JD, Jacobs DR Jr, Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med. 1995;237: 161-168.
44. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974;290:1213-1216.
45. Cazzola M, Ascari E. Red cell ferritin as diagnostic tool. Br J Haematol. 1986;62:209-213.
46. Kohgo Y, Nishisato T, Kondo H, Tsushima N, Niitsu Y, Urushizaki I. Circulating transferrin receptor in human serum. Br J Haematol. 1986; 64:277-281.
47. Chan L-NL, Gerhardt EM. Transferrin receptor gene is hyperexpressed and transcriptionally regulated in differentiating erythroid cells. J Biol Chem. 1992;267:8254-8259.
48. Tuomainen T-P, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT. Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care. 1997;20:426-428.